July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   June 2019
[Retracted] Effect of 3-Hour Normobaric Hyperoxia on Diabetic Macular Edema
Author Affiliations & Notes
  • Robert Minturn
    Surgery- Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Brendan Seto
    Surgery- Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Keiko Yamada
    Surgery- Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Ke Zeng
    Surgery- Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Jorge G Arroyo
    Surgery- Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Robert Minturn, None; Brendan Seto, None; Keiko Yamada, None; Ke Zeng, None; Jorge Arroyo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2019, Vol.60, 2635. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert Minturn, Brendan Seto, Keiko Yamada, Ke Zeng, Jorge G Arroyo; [Retracted] Effect of 3-Hour Normobaric Hyperoxia on Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2635.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This abstract has been retracted.
Abstract
This abstract has been retracted. :

Purpose : Diabetic macular edema (DME) is the most common cause of moderate visual loss in people with diabetes mellitus. It is believed to be partially caused by retinal ischemia and is typically treated with anti-VEGF injections and/or focal laser photocoagulation. We hypothesize that that treatment of patients with diabetic macular edema with normobaric hyperoxia will reduce the amount of retinal ischemia and macular edema.

Methods : Forty-six patients were recruited from the Beth Israel Deaoness Medical Center (BIDMC) Eye Clinic with the diagnoses of diabetic macular edema. They were put on 5 liters per minute of oxygen using a facemask for 3 hours, with Optical Coherence Technology (OCT) Scans taken before and after their session. Macula Edema measurements were derived from a fast raster scan and recorded as the percentage decrease in volume. We utilized two sets of controls: diabetic macular edema patients at BIDMC who received OCT scans before and after a 3-hour clinical visit without any treatment, and data from the DRCR Protocol C, which examined temporal variation in OCT scans in 99 untreated patients. 27 patients were recruited from the Beth Israel Deaconess Medical Center’s Eye Clinic with diagnoses of diabetic macular edema. They were put on 5 Liters per minute of oxygen through a facemask for 3 hours, with Optical Coherence Technology (OCT) Scans taken before and after their session. Macula Edema measurements were derived from a fast raster scan and recorded as the percentage decrease in volume. We utilized two sets of controls: diabetic macular edema patients at BIDMC who received OCT scans before and after a 3-hour clinical visit without any treatment, and data from the DRCR Protocol C, which examined temporal variation in OCT scans in 99 untreated patients.

Results : Patients undergoing 3-hour sessions of normobaric hyperoxia for DME saw significant decreases in their macular edema (μ = 4.2%, p < 0.05). Moreover, the two control groups demonstrated low variability in 3-hour repeated measurements that serve to mitigate the possibility that this change was due to random chance (95% CI for DRCR = [-0.72%,1.1%] and our clinic [-0.89%, 0.91%]).

Conclusions : These results support the hypothesis that DME is associated with retinal ischemia and even short-term, low dose oxygen therapy can lead to a significant reduction in CMT. Further study on this novel treatment modality with worth pursuing.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×